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In prostate adenocarcinoma (PCa), distinction between indolent and aggressive disease is challenging. Around 50% of PCa are
characterized by TMPRSS2-ERG (T2E)-fusion oncoproteins deﬁning two molecular subtypes (T2E-positive/negative). However,
current prognostic tests do not differ between both molecular subtypes, which might affect outcome prediction. To investigate
gene-signatures associated with metastasis in T2E-positive and T2E-negative PCa independently, we integrated tumor
transcriptomes and clinicopathological data of two cohorts (total n = 783), and analyzed metastasis-associated gene-
signatures regarding the T2E-status. Here, we show that the prognostic value of biomarkers in PCa critically depends on the
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T2E-status. Using gene-set enrichment analyses, we uncovered that metastatic T2E-positive and T2E-negative PCa are
characterized by distinct gene-signatures. In addition, by testing genes shared by several functional gene-signatures for their
association with event-free survival in a validation cohort (n = 272), we identiﬁed ﬁve genes (ASPN, BGN, COL1A1, RRM2 and
TYMS)—three of which are included in commercially available prognostic tests—whose high expression was signiﬁcantly
associated with worse outcome exclusively in T2E-negative PCa. Among these genes, RRM2 and TYMS were validated by
immunohistochemistry in another validation cohort (n = 135), and several of them proved to add prognostic information to
current clinicopathological predictors, such as Gleason score, exclusively for T2E-negative patients. No prognostic biomarkers
were identiﬁed exclusively for T2E-positive tumors. Collectively, our study discovers that the T2E-status, which is per se not a
strong prognostic biomarker, crucially determines the prognostic value of other biomarkers. Our data suggest that the
molecular subtype needs to be considered when applying prognostic biomarkers for outcome prediction in PCa.
Introduction
Prostate adenocarcinoma (PCa) is the second most common
cancer in men worldwide, which is often detected in early stages
due to regular screening.1 Although most patients exhibit a
slowly growing indolent tumor that can be treated with active
surveillance,1 15–20% of patients develop an aggressive tumor
requiring intense treatment, which is associated with signiﬁcant
adverse effects.2,3 However, it remains difﬁcult to discriminate
indolent from aggressive PCa,4 wherefore 23–42% of men are
“overtreated” leading to unnecessary therapy-associated morbid-
ity that may affect the quality of life and life expectancy.1,5,6
Furthermore, overtreatment constitutes a signiﬁcant socioeco-
nomic and healthcare burden in the Western world.5 Thus,
novel strategies to discriminate aggressive from indolent disease
are urgently required.
Around 50% of PCa are characterized by chromosomal
rearrangements generating chimeric oncogenes through fusion
of TMPRSS2 with ERG, the latter belonging to the ETS family of
transcription factors.7 TMPRSS2-ERG (T2E) acts as an aberrant
transcription factor with oncogenic properties.7 Prior studies
proved that T2E-positive and T2E-negative PCa constitute
molecularly distinct PCa-subtypes,8,9 which may exploit differ-
ent gene-signatures or pathways to promote PCa malignancy.
A recent study highlighted the importance of certain gene-
signatures for the progression of PCa and suggested several
genes as potential biomarkers.10 Yet, the impact of molecular
alterations such as T2E on these gene-signatures was not speciﬁ-
cally considered.
Here, we combined transcriptome proﬁles and clinicopath-
ological data of two discovery cohorts, and explored gene-
signatures and their associated genes involved in metastasis
depending on the T2E-status. We identiﬁed ﬁve prognostic
biomarkers speciﬁcally suitable for T2E-negative PCa, which
were validated in two additional cohorts. Going beyond prior
studies,8–10 we show that the T2E-status critically determines
the nature of distinct metastasis-associated gene-signatures,
and strongly impacts on prognostic biomarkers.
Methods
Microarray and RNA sequencing (RNA-Seq) data
Two publicly available gene expression datasets with matched
clinicopathological data were downloaded from the Gene Expres-
sion Omnibus (GEO) and The Cancer Genome Atlas (TCGA)
(Supporting Information Table S1). The GEO dataset
(GSE46691) comprised 545 PCa cases proﬁled on Affymetrix
GeneChip Human Exon 1.0 ST arrays.11 Microarray signal
intensities were normalized using the SCAN algorithm of
SCAN.UPC12 and the “pd.huex.1.0.st.v2” annotation13 Bio-
conductor packages with brain array chip description ﬁles (CDF,
huex10sthsentrez, version 21), yielding one optimized probe-set
per gene (gene-level summarization).14 The TCGA PCa dataset
(TCGA-PRAD) contains preprocessed RNA-Seq level 3 data of
497 cases.8 Based on the TNM-classiﬁcation of tumors, we
stratiﬁed both datasets in cases with/without metastasis
(corresponding to N0M0 vs. N > 0 and/or M > 0). As incidence
and aggressiveness may be different in Africans and Afro-
Americans compared to Europeans,1 we ﬁltered—if possible—for
men with European ancestry, which was carried out via principal
component analysis in the TCGA-PRAD-cohort based on com-
mon SNPs identiﬁed by parallel exome sequencing. This resulted
in a ﬁnal TCGA-PRAD-cohort of 384 cases (Fig. 1a).
Determination of the T2E-status
In the TCGA-PRAD-cohort, the T2E-status was inferred by
Torres-García et al. based on RNA-Seq split-reads.15 In the
Affymetrix dataset (GSE46691), the T2E-status was inferred
What’s new?
Genetic rearrangements involving androgen-regulated transmembrane protease serine 2 and genes from the ETS transcription
factor family (T2E), most commonly ERG and ETV1, occur in half of prostate cancers but are currently not considered in risk
predictions. The authors integrate clinical and transcriptomic data from multiple studies and show that the prognostic value of
biomarkers critically depends on the T2E-status. They identify ﬁve biomarkers that predict negative outcome exclusively in
T2E-negative prostate cancers, which has implications for outcome prediction based on the molecular subtype.
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from ERG expression levels, which show high concordance
with the T2E-status.16 Cases were classiﬁed as T2E-positive or
T2E-negative if their individual ERG expression level was
above/below the median ERG expression. To reduce the num-
ber of potentially misclassiﬁed cases, we excluded that 10%
with ERG expression levels between the 45th and 55th percen-
tile (Supporting Information Fig. S1).
Processing of microarray and RNA-Seq data
In both cohorts, we separately determined cancer purity with the
ESTIMATE algorithm.17 Only those cases with a consensus purity
estimation of >60% corresponding to TCGA standard (http://
cancergenome.nih.gov/cancersselected/biospeccriteria) were kept
for downstream analyses (Supporting Information Fig. S2). Next,
we removed cases with <90% gene coverage and those 50% of
genes with the lowest variance across all samples using the
geneﬁlter Bioconductor package.18 Moreover, transcripts or prob-
esets from both cohorts, which could not be unambiguously
annotated with ofﬁcial gene symbols, and genes that were repre-
sented in only one cohort were removed. The unity of both
cohorts corresponded to 3,068 variably expressed genes for
299 cases from the TCGA-PRAD-cohort and 538 cases from the
GSE46691-cohort.
We next stratiﬁed both cohorts according to the T2E-status
resulting in four subcohorts comprising 109 T2E-positive and
190 T2E-negative cases for the TCGA-PRAD-cohort, and
242 T2E-positive and 242 T2E-negative cases for the
GSE46691-cohort. We then calculated in each subcohort sepa-
rately the median fold change of each gene between samples
with/without metastasis at diagnosis. Subsequently, the mean fold
change from the corresponding median fold changes of both
cohorts was calculated separately for T2E-positive and T2E-
negative cases. This yielded two gene lists comprising the unity of
3,068 genes ranked by their mean fold change in T2E-positive
(rGL-pos) and T2E-negative cases (rGL-neg; Fig. 1a).
Gene set enrichment analysis
To identify signiﬁcantly enriched gene-signatures (normalized
enrichment score [NES] >1.6, nominal p < 0.05 and false dis-
covery rate [FDR] q < 0.3) in both preranked lists (rGL-pos
and rGL-neg), we used gene set enrichment analysis (GSEA;
MSigDB v6.2; chemical and genetic perturbations; 1,000 per-
mutations).19 To identify common genes across the top 20 sig-
niﬁcantly enriched gene signatures (highest NES), we extracted
those genes by leading-edge analysis that were involved in >3
gene-signatures. This approach yielded two new top gene-
signature gene lists for T2E-positive and T2E-negative cases
(topGL-pos and topGL-neg; Fig. 2a).
For identiﬁcation of gene-signatures associated with the
expression of identiﬁed marker genes in T2E-negative cases,
GSEA was carried out under the same conditions as described
above. For these cases, ranked gene lists were generated by
calculating for each gene the expression fold change after
stratifying the cohort by their median expression of the given
marker gene (ASPN, BGN, COL1A1, RRM2 or TYMS) into a
high and low expression subgroup. For each of the resulting
ﬁve ranked gene lists, we compared the identiﬁed top
Figure 1. T2E-positive and T2E-negative PCa are characterized by
distinct metastasis-associated gene-signatures. (a) Schematic
displaying the processing pipeline of the transcriptome data from
the TCGA-PRAD- and GSE46691-cohorts, and the generation of
differentially ranked gene lists (rGL-pos and rGL-neg). (b) Venn
diagram showing the top 20 signiﬁcant gene-signatures as identiﬁed
by GSEA of rGL-pos and rGL-neg.
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20 gene-signatures from GSEA between their corresponding
subgroups (low/high expression of the given marker gene).
Identiﬁcation of genes signiﬁcantly associated with
metastasis
For all genes in topGL-pos and topGL-neg the signiﬁcance of
differential expression in PCa patients with/without metastasis at
diagnosis was determined by Mann–Whitney U test.20 All genes
were separately tested in both PCa cohorts (TCGA-PRAD and
GSE46691). Values of p were not adjusted for multiple compari-
sons (signiﬁcance for p < 0.05). Only genes being signiﬁcantly
associated with metastasis in both cohorts were considered for
further analyses.
First validation cohort
For validation of survival analyses in the TCGA-PRAD-cohort,
we used another GEO dataset (GSE16560)21 comprising
272 Swedish PCa cases with microarray expression data (6,100
genes) and corresponding clinical information including
cancer-speciﬁc death and T2E-status (Supporting Information
Table S1).
Survival analysis
Survival analyses were carried out on all samples of the
TCGA-PRAD-cohort and in the Swedish validation cohort
(GSE16560) for all genes of topGL-pos and topGL-neg using
the Kaplan–Meier method and the survival package of R.20,22
For calculation of event-free survival (EFS; event = death,
appearance of a new tumor, metastases and/or relapse), both
cohorts were stratiﬁed according to their intratumoral gene
expression into quartiles, and p values were calculated using a
Mantel–Haenszel test by comparing the patient groups with
the most extreme gene expressions (highest vs. lowest).
To analyze the potential added value of biomarkers in addi-
tion to the Gleason score, Kaplan–Meier survival analyses were
carried out in the same cohorts (TCGA-PRAD, GSE16560)
stratiﬁed by (i) the T2E-status, (ii) the Gleason Grading Group
(GGG; I–III vs. IV/V) and (iii) the intratumoral gene expres-
sion levels of the given gene (low versus high; cut-off = 80th
percentile).
Tissue microarrays and immunohistochemistry
A well-characterized prostatectomy cohort comprising
135 patients with known T2E-status (Supporting Information
Table S2) diagnosed with PCa at the Institute of Pathology of
the University Hospital of Bonn (Germany) was used as a sec-
ond validation cohort.23 The tissue microarray (TMA) cohort
was established with ethics approval of the institutional review
board of the University Hospital Bonn, which waived the need
for written informed consent from the participants.23 TMAs
were constructed from formalin-ﬁxed, parafﬁn-embedded
archived tissue with up to ﬁve cores (diameter: 1 mm) of non-
necrotic tumor tissue per patient. Antigen retrieval was achieved
by ProTaqs IV Antigen-Enhancer (#401602392, Quartett) for
RRM2 and ProTaqs IX Antigen-Enhancer (#401603692,
Quartett) for TYMS. RRM2 was detected with a speciﬁc rabbit–
antihuman RRM2 antibody (1:500, 60 min incubation time;
HPA056994, Atlas Antibodies; https://www.proteinatlas.org/
ENSG00000171848-RRM2/tissue). TYMS was detected with a
speciﬁc rabbit–antihuman TYMS antibody (D5B3; 1:100,
60 min incubation time; #9045, Cell Signaling Technology).
Both primary antibodies were followed by an antirabbit IgG
antibody (MP-7401 ImmPress Reagent Kit) and DAB+ chromo-
gen (K3468, Agilent Technologies, Santa Clara, CA). Slides were
counterstained with hematoxylin Gill’s Formula (H-3401, Vec-
tor). Evaluation of RRM2 immunoreactivity was possible in all
133/135 patient specimens (98.5%) represented on the TMA; for
TYMS, 119/135 patient specimens (88.2%) were evaluable.
RRM2 and TYMS immunoreactivities were quantiﬁed by an
experienced data-blinded uropathologist (YT) as percentage of
positive tumor cells (cytoplasmatic expression). The survMisc
package for R was used for optimal cut-off selection and
Kaplan–Meier survival analyses.20 The following percentages of
Figure 2. T2E-positive and T2E-negative PCa are characterized by
distinct metastasis-associated genes. (a) Schematic of the analysis
pipeline to identify recurrent genes in top metastasis-associated
gene-signatures in T2E-positive and T2E-negative cases. LEA, leading-
edge analysis. (b) Venn diagram showing the overlap of recurrent
genes in top metastasis-associated gene-signatures in T2E-positive
and T2E-negative cases.
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positive cells were used as best cut-offs: ≥3% for RRM2, and
≥5.5% for TYMS.
Data availability
Data of the TCGA-PRAD-cohort8 were downloaded from the
TCGA data portal. Two further cohorts are available at GEO
under the accession codes GSE4669111 and GSE16560.21 The
remaining data that support the ﬁndings of our study are
available from the corresponding author upon reasonable
request.
Results
T2E-positive and T2E-negative PCa are characterized by
distinct metastasis-associated gene signatures
T2E-positive and T2E-negative PCa constitute distinct molec-
ular subtypes.8,9 To decipher molecular differences associated
Figure 3. The prognostic value of identiﬁed biomarkers depends on the T2E-status. Kaplan–Meier survival plots derived from either T2E-
positive or T2E-negative samples from TCGA-PRAD- and GSE16560-cohorts for signiﬁcantly event-free survival (EFS)-associated genes (APOE,
ASPN, BGN, COL1A1, LY96, RRM2 and TYMS) of topGL-neg. Patients were stratiﬁed by their quartile intratumoral gene expression levels of the
given gene. p values were calculated between the lowest (Q1) and highest (Q4) gene expression quartiles using a Mantel–Haenszel test.
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with metastasis in either subtype, we analyzed transcriptome
proﬁles with matched clinicopathological data of two public
cohorts (TCGA-PRAD and GSE46691). Multiple ﬁltering
steps regarding variance and regulation, and determination of
the samples’ T2E-fusion status led to a unity of 3,068 variably
expressed genes (see Methods). Depending on the T2E-status,
we created from this set of genes two gene lists ranked by
their expression fold change between patients with/without
metastasis (rGL-pos and rGL-neg; Fig. 1a). Metastasis was
chosen as a surrogate for PCa aggressiveness, because,
contrary to other common PCa related clinical records, infor-
mation on metastasis was publicly available for both cohorts
and usually indicates aggressiveness in PCa.4 GSEA on rGL-
pos and rGL-neg showed no overlap between the top 20 signif-
icant metastasis-associated gene signatures in T2E-positive
and T2E-negative cases (Fig. 1b, Supporting Information
Table S3).
From those top 20 gene-signatures, we extracted genes
involved in >3 of them by leading-edge analysis to create two
new “top gene-signature” gene lists (topGL-pos and topGL-neg,
Fig. 2a). Accordingly, topGL-pos contained 16 genes of rGL-
pos, recurrent in signiﬁcant gene-signatures of T2E-positive
cases (Supporting Information Table 4), whereas topGL-neg
contained 74 genes recurrent in signiﬁcant gene-signatures
of T2E-negative (rGL-neg) cases (Supporting Information
Table S5). Only two genes (RRM2 and TYMS) were shared
among T2E-positive and T2E-negative cases, but involved in
different gene-signatures (Fig. 2b).
Apart from these protein-coding genes, we explored our
transcriptome data for noncoding genes. In the unity of genes
from both discovery datasets, we found only 20 noncoding
genes comprising lncRNAs, ncRNAs and miRNAs. However,
only one of these noncoding genes (DLEU2) was represented
in a single signiﬁcantly enriched gene-signature (top 20) for
T2E-positive or T2E-negative PCa cases, which precluded a
comprehensive evaluation of the role of noncoding genes in
prognostication of PCa.
Altogether, these results indicated that T2E-positive and
T2E-negative PCa are characterized by distinct metastasis-
associated gene signatures.
Different genes are associated with metastasis in T2E-
positive and T2E-negative PCa
Next, we separately tested whether all genes of our top
gene-signatures gene lists, topGL-pos and topGL-neg
(Fig. 2b), were signiﬁcantly differentially expressed depending
on the presence of metastasis in the TCGA-PRAD- and
GSE46691-cohorts. In T2E-postive cases (topGL-pos), three
genes (GMNN, TROAP and WEE1) out of 16 were signiﬁ-
cantly higher expressed (p < 0.05) in PCa samples with metas-
tasis. In T2E-negative cases (topGL-neg) 29 of 74 genes were
signiﬁcantly (p < 0.05) higher expressed in PCa samples with
metastasis. We found no overlap of these signiﬁcantly differ-
entially expressed and metastasis-associated genes between
T2E-positive and T2E-negative cases (Supporting Information
Tables S4 and S5). These results further suggested that—
depending on the T2E-status—distinct genes are linked to
metastasis in PCa.
Identiﬁcation of subtype-speciﬁc prognostic biomarkers
To test whether the identiﬁed metastasis-associated genes
were correlated with EFS, we performed Kaplan–Meier ana-
lyses in two independent cohorts. The ﬁrst comprised PCa
samples from TCGA-PRAD, the second was derived from
Table 1. Result summary of genes in topGL-neg and topGL-pos that passed ≥1 of our tests (association test and survival analysis) for all
cohorts, as well as those two genes (RRM2, TYMS) which were included in both gene lists (topGL-pos and topGL-neg) (significant genes
extracted from Supporting Information Tables S3 and S4)
TCGA GSE16560
Gene list Gene
GSE46691
p-value
(metastasis)
p-value
(metastasis)
p-value
(EFS)
Expression
level associated
with long EFS
p-value
(EFS)
Expression level
associated with
long EFS
topGL-pos GMNN <0.001 0.005 n.s. low n.s. high
RRM2 0.005 n.s. n.s. high n.s. low
TROAP 0.021 0.032 n.s. low n.s. high
TYMS <0.001 n.s. n.s. high n.s. low
WEE1 <0.001 0.002 n.s. low n.s. high
topGL-neg APOE n.s. 0.011 0.021 low 0.005 low
ASPN <0.001 <0.001 0.001 low <0.001 low
BGN 0.003 <0.001 0.015 low <0.001 low
COL1A1 <0.001 <0.001 0.025 low 0.007 low
RRM2 0.044 <0.001 <0.001 low 0.002 low
LY96 n.s. <0.001 0.001 low 0.043 low
TYMS 0.009 0.018 0.001 low <0.001 low
Genes being significant in all tests are highlighted in bold font.
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another independent microarray-based study (GSE16560, ﬁrst
validation cohort).21 We only accepted genes as being associ-
ated with EFS if they were signiﬁcantly (p < 0.05) and concor-
dantly associated with EFS in both cohorts. While none of the
genes identiﬁed in screening of T2E-positive cases (topGL-
pos) was consistently associated with EFS in both cohorts,
seven genes were consistently associated with EFS in T2E-
negative cases (APOE, ASPN, BGN, COL1A1, LY96, RRM2
and TYMS). For all seven genes, higher expression levels of
the respective gene were associated with shorter EFS (Fig. 3).
Interestingly, the same biomarkers showed no concordant
association with EFS in T2E-positive cases. As displayed in
Table 1, only ﬁve genes (ASPN, BGN, COL1A1, RRM2 and
TYMS) were associated with metastasis and EFS in both dis-
covery cohorts and the ﬁrst validation cohort, indicating that
these genes could be used for outcome prediction exclusively
in T2E-negative PCa.
To explore whether the association of these genes with the
outcome of T2E-negative cases might be confounded by addi-
tional molecular events such as mutations in the SPOP gene
(around 10% of PCa cases8,24), we re-investigated the TCGA-
PRAD-cohort for which the SPOP mutation status could be
inferred from exome sequencing data.8 However, removal of
the 20 cases harboring SPOP mutations from the T2E-
negative TCGA-PRAD subcohort did not affect the signiﬁcant
associations of ASPN, BGN, COL1A1, RRM2 and TYMS with
clinical outcome (not shown), suggesting that SPOP mutations
do not affect the validity of these biomarkers for T2E-negative
PCa cases. Likewise, we tested whether TP53 or PTEN muta-
tions could have impacted our results in the TCGA-PRAD-
cohort (overall mutation frequency of 7 and 2%, respectively).
In the T2E-negative subcohort, we identiﬁed 11 TP53- and
two PTEN-mutated cases. Removal of these cases from this
subcohort did not affect the signiﬁcant associations of ASPN,
BGN, COL1A1, RRM2 and TYMS with clinical outcome (data
not shown). These results indicated that neither TP53 nor
PTEN mutations could have biased our results.
Comparison of gene signatures associated with T2E-
negative PCa stratiﬁed by gene expression
Next, we investigated whether T2E-negative PCa cases with
high gene expression of ASPN, BGN, COL1A1, RRM2 or
TYMS are enriched in different gene signatures as determined
by GSEA compared to cases with low expression of the
corresponding gene. The overlap of the top 20 gene-signatures
(Supporting Information Table S6) identiﬁed by GSEA in sub-
groups with either high or low expression of ASPN, BGN,
COL1A1, RRM2 or TYMS ranged from 15% for COL1A1 to
45% for RRM2 (average overlap across all ﬁve genes: 38%).
These relative low overlaps indicate that T2E-negative PCa
tumors with high or low expression of the given marker can-
didate gene may be driven by largely distinct pathways and as
such may differ in their (patho)biology.
Validation of RRM2 and TYMS as prognostic biomarkers for
T2E-negative cases by IHC
To conﬁrm the T2E-dependent prognostic value of PCa
biomarkers, we stained TMAs containing 135 PCa cases by
Figure 4. Validation of (a) RRM2 and (b) TYMS as prognostic
biomarker for T2E-negative cases by IHC. Top a/b: Representative
micrographs of T2E-positive and -negative PCa stained for (a) RRM2
and (b) TYMS by IHC. Scale bars = 50 μm for 10× and 40×
magniﬁcation, respectively. Bottom a/b: Kaplan–Meier analysis of
biochemical relapse (BCR)-free survival of T2E-positive and
T2E-negative cases stratiﬁed by their best cut-off for (a)
RRM2-positive tumor cells (≥3%) and (b) TYMS-positive tumor cells
(≥5.5%). Mantel–Haenszel test.
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immunohistochemistry (IHC) for RRM2 and TYMS as examples,
as for both proteins speciﬁc antibodies were available. We sepa-
rately analyzed the biochemical recurrence (BCR)-free survival of
T2E-positive and T2E-negative cases stratifying patients by their
percentage of RRM2-positive tumor cells (cut-off ≥3%) as well as
TYMS-positive tumor cells (cut-off ≥5.5%). In these analyses, we
found that patients with T2E-negative PCa exhibiting a high
percentage of RRM2-positive tumor cells had signiﬁcantly worse
BCR-free survival than those with low RRM2-positivity
(p = 0.005) (Fig. 4a). Likewise, we observed a signiﬁcantly lower
Figure 5. Subtype-speciﬁc biomarkers add prognostic information to Gleason grading. (a) Kaplan–Meier analysis of EFS for either T2E-positive
or T2E-negative cases from TCGA-PRAD- and GSE16560-cohorts. Patients were stratiﬁed by their Gleason Grading Group (GGG). Mantel–
Haenszel test. (b) Kaplan–Meier analysis of EFS of cases from the TCGA-PRAD- and GSE16560-cohorts stratiﬁed by their T2E-status, the GGG
(as in a) and by high or low expression (cut-off = 80th percentile) of the indicated biomarker. p values (Supporting Information Table S7)
were calculated with a Mantel–Haenszel test between high and low biomarker expression separately for high (IV/V; red color) and low (I–III;
blue color) GGG.
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BCR-free survival rate for patients with T2E-negative PCa that
presented a high percentage of TYMS-positive tumor cells
(p = 0.004; Fig. 4b). In contrast, no association of either RRM2-
or TYMS-positivity with BCR-free survival was found in T2E-
positive cases.
These results provided further evidence that the prognostic
value of biomarkers in PCa depends on the T2E-status, and
suggested that “pooled” analyses ignoring the T2E-status may
obscure outcome prediction.
Subtype-speciﬁc biomarkers add prognostic information to
Gleason grading
One of the most widely used predictors for patient outcome in
PCa is the established Gleason grading system which reforms
the Gleason score into ﬁve new Gleason Grading Groups (GGG;
I–V)25 that proved to be of high prognostic signiﬁcance in large
cohorts.26,27 However, risk-prediction for individual PCa
patients based on Gleason grading still remains limited.28,29
To test whether our identiﬁed biomarkers may add prognos-
tic information to the Gleason grading, we performed compared
Kaplan–Meier analyses for which we stratiﬁed both cohorts
(TCGA-PRAD, GSE16560) by the T2E-status and subsequently
by the GGG (I–III vs. IV/V). As expected, we observed in both
cohorts a signiﬁcant (p < 0.002) association of worse EFS with
high GGG (IV/V) regardless of the T2E-status (Fig. 5a). We
next explored whether further subgrouping by the potential
subtype-speciﬁc biomarkers would add prognostic information
to the GGG. As displayed in Figure 5b, high RRM2 and TYMS
expression were associated with signiﬁcantly worse outcome in
both GGG-low (I–III) and GGG-high (IV/V) patients if PCa
tumors were T2E-negative. Strikingly, this additive prognostic
effect was entirely absent in both cohorts in T2E-positive cases
(Fig. 5b). Less strong effects were observed for ASPN, BGN and
COL1A1, which showed either statistical trends or reached sta-
tistical signiﬁcance only in one cohort (Fig. 5b). A summary of
the results is given in Supporting Information Table S7.
Taken together, these results indicated that at least two
genes (RRM2, TYMS) of our ﬁve biomarker candidates can
add prognostic information to routine Gleason grading for
T2E-negative patients.
Discussion
Prior studies showed that T2E-positive PCa are associated
with speciﬁc germline susceptibility variants and epigenetic
proﬁles providing evidence that T2E-positive and T2E-
negative PCa constitute distinct molecular and perhaps clini-
cal subtypes.8,9 We hypothesized that differentially expressed
genes involved in distinct gene signatures may be associated
with tumor progression in T2E-positive and T2E-negative
PCa, and that prognostic biomarker may be only relevant in
the context of a speciﬁc molecular subtype.
To explore such molecular differences, we analyzed PCa
transcriptomes and matched clinical data of two large cohorts
(TCGA-PRAD and GSE46691). Applying several ﬁltering
steps and enrichment analyses, we identiﬁed the top 20 metas-
tasis-associated gene-signatures for T2E-positive and T2E-
negative cases. Strikingly, these gene-signatures showed no
overlap, emphasizing that T2E-positive and T2E-negative PCa
are distinct molecular subtypes that take different routes on
disease progression.8,9 From these subtype-speciﬁc gene-signa-
tures, we extracted overrepresented genes (topGL-pos and
topGL-neg) of which ﬁve (ASPN, BGN, COL1A1, RRM2,
TYMS) proved to be of high value for risk-prediction exclu-
sively in T2E-negative PCa. These results imply that bio-
markers for risk-prediction in PCa should be used dependent
on the PCa-subtype to maximize their prognostic power.
For example, Asporin (ASPN) and Biglycan (BGN)30 are
both known to be associated with PCa progression31 and poor
prognosis.32 Our results conﬁrm these previous observations
but highlight that they have only prognostic value for T2E-
negative cases. Jacobsen et al. additionally reported that BGN
expression may be related to the presence of the T2E-fusion.32
However, our results showed that in T2E-positive PCa, BGN
is not involved in the top gene-signatures associated with
metastasis, unlike in T2E-negative PCa.
The protein product of the COL1A1 gene (collagen type I
alpha 1), which is a major constituent of the extracellular
matrix and connective tissues30 has hitherto not been reported
to be linked with outcome of PCa patients rendering COL1A1
a novel potential biomarker for T2E-negative PCa.
RRM2 (ribonuclease reductase regulatory subunit M2)
plays a role in DNA synthesis,30 and its overexpression can
promote tumor progression.33 In fact, a study not dis-
tinguishing molecular PCa-subtypes suggested that RRM2
overexpression may be associated with PCa progression.10
Our ﬁndings made on the mRNA and protein level are in line
with these ﬁndings with the important reﬁnement that RRM2
has strong prognostic power in T2E-negative cases while hav-
ing no prognostic value in T2E-positive cases as conﬁrmed in
four independent PCa cohorts.
Similar observations were made for TYMS (thymidylate
synthetase), which is involved in DNA replication and repair30
and reported to correlate with worse outcomes in PCa.34 We
observed that T2E-negative patients had signiﬁcantly higher
risk for short EFS with high TYMS expression—an effect that
was absent in T2E-positive cases.
In another pathway analysis focusing only on T2E-negative
cases, we identiﬁed different gene-signatures for cases with
high and low expression of ASPN, BGN, COL1A1, RRM2 or
TYMS. The limited average overlap of only 38% between the
top 20 gene signatures in cases with high or low expression of
the given marker gene may indicate that these PCa tumors
differ in their (patho)biology.
In accordance with our ﬁnding that the T2E-status, which is
per se not a strong prognostic biomarker, is crucially determining
the prognostic value of other biomarkers, it has been shown
that the proliferation marker Ki-67 is especially prognostic in
T2E-negative cases.35,36
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A common clinicopathological marker used in the routine
clinical setting for PCa risk-prediction is the Gleason score or
the recently established Gleason grading system which
reforms the Gleason score into ﬁve new Gleason Grading
Groups (GGG; I–V).25 In our comparative survival analyses,
the GGG outperforms the identiﬁed subtype-speciﬁc bio-
markers. However, two subtype-speciﬁc biomarkers (RRM2,
TYMS) proved to add further prognostic information exclu-
sively for T2E-negative cases. Whether the other three bio-
markers may have additional prognostic value has to be tested
in larger cohorts. Yet, the availability of suitable anti-RRM2,
anti-TYMS and anti-ERG antibodies enable a rapid transla-
tion of our ﬁndings in the clinic through the detection of the
T2E-status, the RRM2 and TYMS expression levels by IHC, in
conjunction with Gleason grading on routine histology.
Besides T2E-positive PCa, there are emerging additional
molecular PCa subtypes characterized by rare ETS transloca-
tions or mutations in putative driver genes such as SPOP,
FOXA1 and IDH1.8 In our analyses, mutations in SPOP, which
constitute after T2E-fusions the second most frequent mutated
gene in PCa (around 10%),8,24 had no impact on the validity of
ASPN, BGN, COL1A1, RRM2 and TYMS for outcome predic-
tion in T2E-negative cases. However, whether less frequently
occurring mutations in other genes such as FOXA1 and IDH1
(mutation frequencies: 1.7 and 0.3% in the TCGA-PRAD-
cohort, respectively) impact on biomarker prediction remains
to be determined in future studies with larger sample size.
Additionally, we investigated common cancer-driving muta-
tions in TP53 and PTEN, which are known to be enriched in
PCa.24 With an overall frequency of 7% in the TCGA-PRAD-
cohort, TP53 was equally distributed in T2E-positive and nega-
tive cases and did not bias our results of the survival analyses.
Similarly, the number of PTEN-mutated cases (overall frequency
of 2%) was negligible in the TCGA-PRAD-cohort.
The recently developed genomic Decipher test for PCa,
which was based on one of the studies used here (GSE4669111),
enables risk-stratiﬁcation of PCa patients after surgery by evalu-
ating the expression pattern of 22 genes,11,37 which was con-
ﬁrmed by multiple studies in the clinical setting.38–40
Interestingly, none of our identiﬁed subtype-speciﬁc biomarkers
is among the 22 Decipher genes, probably because this test does
not discriminate between T2E-positive and T2E-negative cases.
Similarly, other genomic tests such as Oncotype DX and
Prolaris do not consider the molecular PCa-subtype,41,42 but
have a concordance between their tested markers and our iden-
tiﬁed T2E-negative speciﬁc markers. While Prolaris is testing
among 32 markers also for RRM2,41 Oncotype Dx has tests for
22 transcripts including BGN and COL1A1.42 Unfortunately, a
direct comparison between the predictive genes of each of these
genomic tests and our candidate genes was not possible,
because the unity of our variably expressed genes only covered
a fraction of the genes necessary for these tests. Thus, it
remains to be explored if and how subtype-speciﬁc prognostic
genes affect the accuracy of such tests when including informa-
tion on the T2E-status.
Finally, it remains to be determined whether the T2E-
status is the only factor inﬂuencing the differential expression
and/or activity of ASPN, BGN, COL1A1, RRM2 and TYMS in
PCa, or whether other alterations, for example, on the epige-
netic level, may play a role in regulation of these genes.
Conclusions
Our study exempliﬁes the power of integrating comprehensive
“omics” and clinical data to identify subtype-speciﬁc bio-
markers in PCa, and suggests that the T2E-status should be
considered when applying prognostic biomarkers to improve
risk prediction of PCa patients in personalized medicine.
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